SEC Form 4 · accession 0001193125-26-361489
Aardvark Therapeutics, Inc. · AARD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chi
Director
Period of report
Aug 14, 2026
Accepted (ET)
Aug 21, 2026 · 7:48 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001774857
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $6.54 | Aug 14, 2026 | A | 44,964 | A | — | Aug 14, 2036 | Common Stock | 44,964 | 44,964 | D |
Explanation of responses
- F1The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive.